Jon Caulkins, Jonathan Kulick, and I have an op-ed in Friday’s Financial Times. It’s behind a registration wall (though not a paywall), but here’s the nut graf:
There simply are not many feasible drug-control activities in Afghanistan that do more good than harm. This is a case where less really is more: since the natural tendency of counterdrug efforts is to help our enemies, we should pursue those efforts as little as possible. As a first step in breaking the Taliban’s momentum, we might stop filling its coffers.
And here’s the full report.